Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 13/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176354 | 0.83 | L3MBTL1 (0.42) | POLBDTYMKELANEDDB1CRBN | |
| SCHEMBL29773369 | 0.83 | L3MBTL1 (0.42) | POLBDTYMKELANEDDB1CRBN | |
| SCHEMBL25703825 | 0.82 | POLB (0.41) | POLBDTYMKELANEDDB1CRBN | |
| SCHEMBL3606964 | 0.82 | DTYMK (0.42) | POLBDTYMKELANEDDB1CRBN | |
| SCHEMBL15902469 | 0.80 | MAP2K4 (0.43) | ELANEKDM4EMEN1NPC1RAB9A | |
| SCHEMBL29443983 | 0.80 | MAP2K4 (0.43) | ELANEKDM4EMEN1NPC1RAB9A | |
| SCHEMBL2883080 | 0.79 | POLB (0.41) | POLBDTYMKELANEDDB1CRBN | |
| SCHEMBL29587624 | 0.79 | POLB (0.41) | POLBDTYMKELANEDDB1CRBN | |
| SCHEMBL30991722 | 0.78 | POLB (0.40) | POLBDTYMKELANEDDB1CRBN | |
| SCHEMBL13797879 | 0.78 | ELANE (0.33) | ELANEGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404856-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20100256181-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256181-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256181-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| WO-2009067166-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256181-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLB, POLR2A, RRM2B | POLB 1/4885DTYMK 156/4885ELANE 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.